Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).
Joyce O'Shaughnessy
Honoraria - Johnson & Johnson
Mario Campone
Consultant or Advisory Role - Novartis; SERVIER
Honoraria - Novartis; SERVIER
Etienne Brain
No relevant relationships to disclose
Patrick Neven
No relevant relationships to disclose
Daniel F. Hayes
Research Funding - Janssen Pharmaceutical
Igor Bondarenko
No relevant relationships to disclose
Thomas W. Griffin
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Jason L. Martin
Employment or Leadership Position - Janssen-Cilag
Stock Ownership - Johnson & Johnson
Peter De Porre
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Janssen Pharmaceutical ; Johnson & Johnson
Thian San Kheoh
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Margaret K. Yu
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Weimin Peng
Employment or Leadership Position - Janssen Research & Development
Stephen R. D. Johnston
No relevant relationships to disclose